Saturday, 22 August 2015

A Guide to Minimal Use of Neuroleptics: Why and How: Volkmar Aderhold, Peter Stastny @Mad_In_America

'A Guide to Minimal Use of Neuroleptics: Why and How' by Volkmar Aderhold MD & Peter Stastny MD, June 2015, on Mad in America:

"This new MIA publication, by German psychiatrist Volkmar Aderhold and American psychiatrist Peter Stastny, provides a thorough, evidence-based rationale for rethinking the prescribing of antipsychotics. The PDF may be downloaded for free."

[Authors’ affiliation: Volkmar Aderhold, Institute for Social Psychiatry at the University of
Greifswald, Germany. Peter Stastny: Department of Epidemiology, Columbia University, New


In preparing this review, we are hoping that it will encourage people to become actively engaged with the use of neuroleptics in the treatment of individuals experiencing psychotic symptoms. Overall, it represents a critical discourse concerning the use of these medications and their indications, as well as any problems associated with them.  These perspectives are embedded in a scientific context to emphasize that this is not an ideological discussion, but rather an attempt to promote scientifically founded decisions on the behalf of clients. Consequently, a key portion of this contribution addresses the issue of “What to do?” Responding to patients’ needs means finding ways of utilizing these medications that offer the greatest benefits, with the fewest possible unwanted effects, for individuals experiencing psychoses. In addition, it deals with the ways in which neuroleptics can be most effectively and reasonably combined with other interventions. The aim of treatment is always to keep patients’ well being in mind.

Since we hope that the readership of this review will include lay readers as well as those considered “experts” or “methodologists,” we have chosen to define many technical terms in the text. We have provided references for the scientific material that is being citied, with a full listing of references at the end of the text. ..."

page 102
 Read full 135 page publication

Wednesday, 19 August 2015

'A Milestone in the Battle for Truth in Drug Safety' @DrDavidHealy Study 329

A Milestone in the Battle for Truth in Drug Safety: Dr David Healy, 17 August 2015:

Study 329: The final chapter coming soon
"Arguably the most controversial drug study ever, Study 329, published in July 2001:
  1. Concluded that paroxetine was a safe and effective medication for treating major depression in adolescents;
  2. Is still widely cited in the medical literature, providing physicians with assurance about the usefulness of paroxetine;
  3. Was criticized by a few alert and concerned journalists and academics. Their voices were buried by a tsunami of positive marketing and promotion by vested interests;
  4. Resulted in a successful New York state fraud lawsuit against GSK;
  5. Resulted in 2012 in the biggest fine in corporate history – $3 Billion; and
  6. Remains unretracted.

Paroxetine Names Around the World

In June, 2013 Peter Doshi and colleagues published “Restoring invisible and abandoned trials: a call for people to publish the findings” in the British Journal of Medicine (BMJ).

They referred to this proposed protocol as RIAT, and described its purpose as follows:

Unpublished and misreported studies make it difficult to determine the true value of a treatment. Peter Doshi and colleagues call for sponsors and investigators of abandoned studies to publish (or republish) and propose a system for independent publishing if sponsors fail to respond.

A team of researchers undertook to re-analyze the original data and publish a new analysis under the RIAT protocol.

In August, 2015, after a year and seven drafts, BMJ notified the team that their submission would be published in September, 2015. This will be the first ever trial with two completely different takes on the same data.

This new study, Restoring Study 329: Efficacy and harms of paroxetine and imipramine in the treatment of adolescent major depression: restoration of a randomised controlled trialshould shock all who care about integrity in drug safety. Find out the inside story when a new site, Restoring Study 329, goes live."